Cargando…
Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318489/ https://www.ncbi.nlm.nih.gov/pubmed/37409110 http://dx.doi.org/10.1002/mco2.322 |
| _version_ | 1785068048515858432 |
|---|---|
| author | Zhou, Yunxiang Wang, Xiaojia Chen, Yiding |
| author_facet | Zhou, Yunxiang Wang, Xiaojia Chen, Yiding |
| author_sort | Zhou, Yunxiang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10318489 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103184892023-07-05 Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer Zhou, Yunxiang Wang, Xiaojia Chen, Yiding MedComm (2020) Highlights John Wiley and Sons Inc. 2023-07-04 /pmc/articles/PMC10318489/ /pubmed/37409110 http://dx.doi.org/10.1002/mco2.322 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Highlights Zhou, Yunxiang Wang, Xiaojia Chen, Yiding Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer |
| title | Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer |
| title_full | Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer |
| title_fullStr | Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer |
| title_full_unstemmed | Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer |
| title_short | Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer |
| title_sort | margetuximab: an active alternative for later‐line therapy in patients with her2‐positive advanced breast cancer |
| topic | Highlights |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318489/ https://www.ncbi.nlm.nih.gov/pubmed/37409110 http://dx.doi.org/10.1002/mco2.322 |
| work_keys_str_mv | AT zhouyunxiang margetuximabanactivealternativeforlaterlinetherapyinpatientswithher2positiveadvancedbreastcancer AT wangxiaojia margetuximabanactivealternativeforlaterlinetherapyinpatientswithher2positiveadvancedbreastcancer AT chenyiding margetuximabanactivealternativeforlaterlinetherapyinpatientswithher2positiveadvancedbreastcancer |